Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Epigenetic Oncology and Extracellular Histone-Targeted Inflammatory Disease Therapeutics.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for H4C8 / Histone H4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | H4C8 Recombinant Histone H4 Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW: 11.4 kDa. (Note: Mature protein sequence is identical across H4 paralogs). |
View H4C8 Products |
| Gene Delivery | H4C8 Promise-ORF / Lentivirus Full-length ORF with unique 3' UTR sequence for paralog-specific expression and stable cell line construction. |
View H4C8 Products |
| Benchmark Ab | Anti-Histone H4 Recombinant Antibody Recombinant positive control for chromatin immunoprecipitation (ChIP) and neutralization assays. |
View H4C8 Products |
| Validator | H4C8 siRNA Set Targeting unique UTR regions to selectively knock down the H4C8 transcript without affecting other H4 paralogs. |
View H4C8 Products |
| Related Target A | HDAC1 Histone deacetylase 1; key eraser of Histone H4 acetylation marks. |
View HDAC1 Products |
| Related Target B | EP300 Histone acetyltransferase p300; key writer of Histone H4 lysine acetylation. |
View EP300 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Paralog Cross-Reactivity (H4C1 to H4C15) | Unique 3' UTR-targeted siRNA sequences and sequence-verified plasmid inserts to distinguish H4C8 at the transcript level. |
| Post-Translational Modification (PTM) Interference | Recombinant proteins expressed in controlled E. coli systems to provide a clean, unmodified baseline sequence for in vitro enzymatic assays. |
| Lack of Controls | Sequence-verified clinical-grade benchmark antibodies for target engagement verification. |
| False Positives in Chromatin Assays | Highly purified (>95% by SDS-PAGE) histone complexes to ensure clean macromolecular assembly. |
Live H4C8 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Histone H4 (including the H4C8 gene product) is bifurcating into two major clinical pathways. In oncology, drug discovery focuses on epigenetic modulation, where small molecule inhibitors target the "writers," "erasers," and "readers" of Histone H4 post-translational modifications (such as H4K16ac and H4K20me3). Concurrently, in acute inflammatory conditions like sepsis, ARDS, and thrombosis, extracellular Histone H4 acts as a major damage-associated molecular pattern (DAMP). Neutralizing antibodies directed against extracellular Histone H4 are currently entering clinical evaluation to curb systemic inflammatory cascades without compromising intracellular chromatin structure.
Because the mature protein sequence of H4C8 is 100% identical to other canonical Histone H4 paralogs (such as H4C1), therapeutic strategies targeting the chromatin-bound protein itself cannot differentiate between these genomic loci. Consequently, current clinical programs target either the universal Histone H4 structural features or utilize transcript-specific nucleic acid therapeutics (such as siRNA or antisense oligonucleotides) to selectively downregulate H4C8 in disease states where specific gene loci are aberrantly activated.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Neutralizing mAb | Academic Medical Centers, Biotech Startups | Sepsis, Autoimmune Diseases, Thrombosis | Extracellular Histone Binding Assay (Requires high-purity, low-endotoxin recombinant H4 proteins) |
| Small Molecule (Epigenetic) | Incyte, Novartis, Bristol Myers Squibb | Hematological Malignancies, Solid Tumors | In vitro Methylation/Acetylation Assays (Requires unmodified recombinant proteins as substrates) |
| RNA Therapeutics (siRNA/ASO) | Alnylam, Ionis Pharmaceuticals | Oncological indications with H4C8 amplification | Paralog-specific knockdown verification (Requires sequence-verified siRNA and isoform-specific qPCR controls) |